Afuco™ Anti-CTLA4 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-206) (CAT#: AFC-TAB-206)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CTLA4. It is a fully human IgG2 monoclonal antibody, undergoing human trials for the treatment of cancer.
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.

(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000163599-CTLA4

(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000163599-CTLA4
Specifications
- Immunogen
- Human CTLA-4.
- Host Species
- Human
- Derivation
- Human
- Type
- ADCC enhanced antibody
- Species Reactivity
- Human
- Applications
- IF, IP, Neut, FuncS, ELISA
- Conjugate
- Unconjugated
- Generic Name
- Ticilimumab (= Tremelimumab)
Product Property
- Purity
- >95% by SDS-PAGE
- Storage
- Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- CTLA4; cytotoxic T-lymphocyte-associated protein 4; celiac disease 3, CELIAC3; cytotoxic T-lymphocyte protein 4; CD; CD28; CD152; GSE; ICOS; CD152 isoform; celiac disease 3;
- Gene ID
- 1493
- UniProt ID
- P16410
Related Resources
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Ticilimumab (= tremelimumab)"
Anti-Human CTLA4 Recombinant Antibody (Ticilimumab (Tremelimumab))Recombinant monoclonal antibody to CTLA4. Tremelimumab (formerly ticilimumab, CP-675,206) is a fully human IgG2 monoclonal antibody, undergoing human trials for the treatment of cancer.
See other products for "CTLA4"
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-067 | Anti-Human CTLA4 Recombinant Antibody (TAB-067) | WB, FuncS, IF, Neut, ELISA, FC, IP | IgG1 - kappa |
TAB-206 | Anti-Human CTLA4 Recombinant Antibody (Ticilimumab (Tremelimumab)) | WB, IF, IP, Neut, FuncS, ELISA, FC | IgG2 |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for AFC-TAB-206. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: IF, IP, Neut, FuncS, ELISA, FC, WB
Application: ELISA, IP, FC, FuncS, Neut, IF, IHC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: FuncS, IF, Neut, ELISA, FC, IP, IHC
Application: WB, ELISA, FuncS
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: ELISA, WB, FC
Application: ELISA, Neut
Application: ELISA, FC, FuncS
For Research Use Only. Not For Clinical Use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.